Amino Sequence

Amino Sequence is a research compound supplier with 30 active listings on Peptides.SO, offering a catalog focused on GLP receptor agonist compounds, tissue healing peptides, anti-aging and longevity research agents, cognitive peptides, and NAD+ formulations. The company's product architecture reflects broad multi-category positioning, with particularly strong coverage of combination formulations and novel research compound classes including the FOXO4-DRI apoptosis-induction peptide — a distinguishing specialty entry within the broader research supplier market.

The GLP receptor research lineup encompasses the complete contemporary triad: GLP-1 (Semaglutide, 5mg–20mg, multiple sizes), GLP-2 (Tirzepatide), and GLP3 (Retatrutide), alongside the CagriSema 10mg/10mg combination (Cagrilintide + Semaglutide) and CagriTirz 20mg (Cagrilintide + Tirzepatide). These combination formats address researchers studying the compounding effects of amylin/GLP-1 co-agonism and GIP/GLP-1/amylin multi-receptor signaling — research territories of high contemporary interest in metabolic biology. GLP3/CAGRI 20mg/4mg provides yet another dual-compound configuration for researchers designing combination GLP/amylin receptor studies.

Tissue repair compounds are a well-represented segment. BPC-157 and TB-500 are available individually and as a 10mg/10mg blend in 10-vial kits, serving researchers who require both compounds for synergistic healing-biology study designs. BPC-157 (Body Protection Compound-157) has been documented in preclinical models of gastrointestinal mucosal healing, tendon repair, ligament regeneration, and anti-inflammatory signaling. TB-500 (Thymosin Beta-4) supports actin dynamics, wound healing, and cardiac tissue research.

Amino Sequence's verified per-mg pricing: GHK-Cu at $0.55/mg (100mg powder), KLOW Blend at $1.19–$1.44/mg (80mg), SS-Mito at $2.90/mg (50mg), and BPC-157 at $6.00/mg (10mg, gift-with-purchase listing). CagriTirz (Cagrilintide/Tirzepatide blend) runs $6.75/mg (20mg). The GHK-Cu bulk powder pricing is among the lowest for that compound across the peer group.

FOXO4-DRI is a specialty entry that sets Amino Sequence apart from most catalog-broad research vendors. FOXO4-DRI is a stapled peptide designed to interfere with the interaction between FOXO4 and p53 in senescent cells, studied for its ability to selectively trigger apoptosis in senescent cells — a research frontier in cellular senescence biology and aging model research. Its presence in the catalog indicates positioning toward longevity and cellular biology research audiences.

The anti-aging and longevity segment is further reinforced by Epithalon (available in standard vials and a pre-mixed pen format at 100mg), SS-Mito 50mg (a mitochondrial-targeting peptide), and Glutathione. The CJC/Ipamorelin Blend covers growth hormone-axis research. The Tesamorelin/Ipamorelin combination supports GHRH analog + GHRP combination research designs. NAD+ and 5-Amino-1MQ address nicotinamide metabolism and cellular energy research. SLU-PP-332 covers ERR agonist exercise-mimetic pharmacology. MOTS-c supports mitochondrial biology and metabolic adaptation research. Bacteriostatic water (BAC 2ml) is listed for reconstitution purposes. All Amino Sequence products are sold exclusively for laboratory and in-vitro scientific research and are not intended for human or veterinary use.